|
|
|
| Study of Co-encapsulated Doxorubicin and Curcumin Poly(butyl cyanoacrylate) Nanoparticles and Reversion of Multidrug Resistance in MCF/ADR Cell Line |
| WU Jun1, YAN Xin1, SHAO Rong1, DUAN Jing-hua2 |
1. School of Chemical and Biological Engineering of Yancheng Institute of Technology, Yancheng 224051, China;
2. Department of Pharmaceutical Sciences-Drug Development Division, College of Pharmacy, University of Kentucky, Lexington, KY 40536-0596, USA |
|
|
|
Abstract Co-encapsulated doxorubicin and curcumin in PBCA nanoparticles were prepared with emulsion polymerization. The mean particle size and the zeta potential of DOX-CUR-PBCA-NPs were 133 ? 5.34nm in diameter and +32.23 ? 4.56 mV, respectively. The entrapment efficiencies of DOX and CUR were 49.98 ? 3.32% and 94.52 ? 3.14%, respectively. Anticancer activities and reversal efficacy of the formulations and various combination approaches were assessed using MTT assay and western blotting. The results showed that the dual-agent loaded PBCA-NPs system had the similar cytotoxicity to co-administration of two single-agent loaded PBCA-NPs (DOX-PBCA-NPs + CUR-PBCA-NPs), which was slightly higher than that of the free drug combination (DOX-CUR) and one free drug/another agent loaded PBCA-NPs combination (DOX+CUR-PBCA-NPs or CUR+DOX-PBCA-NPs). The simultaneous administration of DOX and CUR could achieve the highest reversal efficacy, and down-regulate of P-gp in MCF-7/ADR cell lines. Multidrug-resistant can be enhanced by treated combination of encapsulated cytotoxic drugs and reversal agents. Co-encapsulation of anticancer drug DOX and reversal agent CUR can be more effective in reversing multi-drug resistance than the other formulations and might cause lower normal tissue drug toxicity and fewer drug-drug interactions.
|
|
Received: 12 March 2012
Published: 25 May 2013
|
|
|
|
|
[1] Radhakrishna P G, Srivastava A S, Hassanein T L, et al. Induction of apoptosis in human lung cancer cells by curcumin. Cancer Lett, 2004, 208(2): 163-170.
[2] Song T Q, Duan Z L, Peng L, et al. Apoptosis-inducing effects of curcumin derivatives in human bladder cancer cells. Anti-Cancer Drugs, 2006, 17(3): 279-287.
[3] Odot J, Albert P, Carlier A, et al. In vitro and in vivo anti-tumoral effect of curcumin against melanoma cells. Int J Cancer, 2004, 111(3): 381-387
[4] Stavrovskaya A A. Cellular mechanisms of multidrug resistance of tumor cells. Biochemistry Mosc, 2000, 65(1): 95-106.
[5] 马强,张振书. 中药逆转肿瘤多药耐药研究进展. 湖南中医学院学报,2002,12(22):70-72. Ma Q, Zhang Z S. Progress of traditional Chinese medicine on multidrug resistance. Journal of Hunan College of Traditional Chinese Medicine, 2002, 12(22): 70-72.
[6] Guo L Y, Cai X F, Lee J J, et al. Comparison of suppressive effects of demethoxycurcumin and bisdemethoxycurcumin on expressions of inflammatory mediators in vitro and in vivo. Archives of Pharmacal Research, 2008, 31(4): 490-496.
[7] Kunnumakkara A B, Anand P, Aggarwal B B. Curcumin inhibits proliferation, invasion, angiogenesis and metastasis of different cancers through interaction with mltiple cell signaling proteins. Cancer Letters, 2008, 269(2): 199-225.
[8] Aggarwal B B, Harikumar K B. Potential therapeutic effects of curcumin, the anti-inflammatory agent, against neurodegenerative, cardiovascular, pulmonary, metabolic, autoimmune and neoplastic diseases. Int. J. Biochem. Cell Biol, 2009, 1: 40-59.
[9] Aggarwal B B, Kumar A, Bharti A C. Anticancer potential of curcumin: Preclinical and clinical studies. Anticancer Res, 2003, 23: 363-398.
[10] Aggarwal B B, Shishodia S, Takada Y, et al. Curcumin suppresses the paclitaxel-induced nuclear factor-kappaB pathway in breast cancer cells and inhibits lung metastasis of human breast cancer in nude mice. Clinical Cancer Res, 2005, 11: 7490-7498.
[11] 梁广,田吉来,邵丽丽,等. 姜黄素的构效关系及以其为先导物的抗肿瘤化合物研究进展. 化学通报,2008,71(2):110-117. Liang G, Tian J L, Shao L L, et al. Progress in the research on SAR and development of antitumor curcuminoids. Chemistry, 2008, 71(2):110-117.
[12] Chattopadhyay I, Biswas K, Bandyopadhyay U, et al. Turmeric and curcumin: biological actions and medicinal applications. Curr Sci, 2004, 87 (1): 44-53.
[13] Hou X L, Takahashi K, Tanaka K, et al. Curcuma drugs and curcumin regulate the expression and function of P-gp in Caco-2 cells in completely opposite ways. Int J Pharm, 2008, 358(1): 224-229.
[14] Angelini A, Iezzi M, Di F C, et al. Reversal of P-glycoprotein-mediated multidrug resistance in human sarcoma MES-SA/Dx-5 cells by nonsteroidal anti-inflammatory drugs. Oncol Rep, 2008, 20(4): 731-735.
[15] Andjelkovic T, Pesic M, Bankovic J, et al. Synergistic effects of the purine analog sulfinosine and curcumin on the multidrug resistance human non-small cell lung carcinoma cell line(NCI-H460/R). Cancer Biol Ther, 2008, 7(7): 1024-1032.
[16] Labbozzetta M, Notarbartolo M, Poma P, et al. Curcumin as a possible lead compound against hormone-independent, multidrug-resistance breast cancer. Ann N Y Acad Sci, 2009, 1155: 278-283.
[17] Dhandapani K M, Mahesh V B, Brann D W. Curcumin suppresses growth and chemoresistance of human glioblastoma cells via AP-1 and NF-κB transcription factors. J Neurochem, 2007, 102(2): 522-538.
[18] 林溪,许建华,柯丹如. 姜黄素与阿霉素联合用药的体外抗肿瘤作用.中国药理学通报,2000,16(5):522-525. Lin X, Xu J H, Ke D R. Curcumin and doxorubicin in vitro anti-tumor effect of combination therapy. Chinese Pharmacological Bulletin, 2000, 16(5): 522-525.
[19] 薛妍,刘宝瑞,慕利梅. 姜黄素和阿霉素联合应用对人肝癌细胞SMMC-7721抑制作用的研究. 肿瘤研究与临床,2000,12(6):372-374. Xu Y, Liu B R, Mu L M. The combination of curcumin and doxorubicin on human hepatoma cell line SMMC-7721 inhibition studies. Cancer Research and Clinical, 2000, 12(6): 372-374.
[20] 李一诗,傅仲学. 姜黄素逆转肿瘤多药耐药的研究进展. 重庆医学,2010,39(16):2225-2227. Li Y SH, Fu Z X. Progress in reversal of multidrug resistance by curcumin. Chongqing Medical, 2010, 39(16): 2225-2227.
[21] Berta Sanchez de Juan. The analysis of doxorubicin-loaded poly(butylcyanoacrylate) nanoparticles in in vitro glioma models: [Doctor's thesis]. Frankfurt: University of Frankfurt, 2005.
[22] Vauthier C, Dubernet C, Fattal E, et al. Poly(alkylcyanoacrylates) as biodegradable materials for biomedical applications. Adv Drug Delivery Rev, 2003, 55: 519-548.
[23] Soma C E, Dubernet C, Bentolila D, et al. Reversion of multidrug resistance by co-encapsulation of doxorubicin and cyclosporin A in polyalkylcyanoacrylate nanoparticles. Biomaterials, 2000, 21: 1-7.
[24] Nemati F, Dubernet C, Fessi H, et al. Reversion of multidrug resistance using nanoparticles in vitro: Influence of the nature of the polymer. Int J Pharm, 1996, 138(2): 237-246. |
|
Viewed |
|
|
|
Full text
|
|
|
|
|
Abstract
|
|
|
|
|
Cited |
|
|
|
|
| |
Shared |
|
|
|
|
| |
Discussed |
|
|
|
|
